Syndax Pharmaceuticals (1T3) Stock Forecast & Price Target

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1T3 Analyst Ratings

Strong Buy

10 Buy

0 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Syndax

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1T3 Stock 12 Month Forecast

Average Price Target

€31.94

▲(79.01% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Syndax Pharmaceuticals in the last 3 months. The average price target is €31.94 with a high forecast of €48.76 and a low forecast of €22.24. The average price target represents a 79.01% change from the last price of €17.84.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"€7","28":"€28","49":"€49","17.5":"€17.5","38.5":"€38.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48.75795504,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€48.76</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.935034879999993,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€31.94</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.240470719999998,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€22.24</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,17.5,28,38.5,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.905,19.35522731076923,21.805454621538463,24.255681932307695,26.705909243076924,29.156136553846153,31.606363864615385,34.05659117538462,36.50681848615385,38.957045796923076,41.407273107692305,43.85750041846154,46.30772772923077,{"y":48.75795504,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.905,18.061156529230768,19.21731305846154,20.373469587692306,21.529626116923076,22.685782646153843,23.84193917538461,24.99809570461538,26.15425223384615,27.310408763076918,28.466565292307685,29.622721821538455,30.778878350769222,{"y":31.935034879999993,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.905,17.315420824615387,17.72584164923077,18.136262473846156,18.546683298461538,18.957104123076924,19.367524947692306,19.777945772307692,20.188366596923075,20.59878742153846,21.009208246153843,21.41962907076923,21.83004989538461,{"y":22.240470719999998,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.45,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.4,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.9,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.3,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.485,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.725,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.96,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.905,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€48.76

Average Price Target€31.94

Lowest Price Target€22.24

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Dai

UBS

€31.65→€28.23

Buy

58.23%

Upside

Assigned

08/21/26

Syndax price target lowered to $33 from $37 at UBSSyndax price target lowered to $33 from $37 at UBS

Stephen Willey

Stifel Nicolaus

€34.22

Buy

91.79%

Upside

Reiterated

08/14/26

Analysts' Top Healthcare Picks: Ascendis Pharma (ASND), Quantum-Si (QSI)

Anupam Rama

J.P. Morgan

€37.64→€34.22

Buy

91.79%

Upside

Reiterated

08/11/26

Syndax price target lowered to $40 from $44 at JPMorganSyndax price target lowered to $40 from $44 at JPMorgan

Etzer Darout

Barclays

€31.65

Buy

77.41%

Upside

Reiterated

08/05/26

Analysts' Top Healthcare Picks: Syndax Pharmaceuticals (SNDX), Align Tech (ALGN)

Andres Y. Maldonado

H.C. Wainwright

€34.22→€32.51

Buy

82.20%

Upside

Reiterated

08/05/26

Syndax price target lowered to $38 from $40 at H.C. WainwrightSyndax price target lowered to $38 from $40 at H.C. Wainwright

Jason Zemansky

Bank of America Securities

€22.24

Buy

24.67%

Upside

Reiterated

08/05/26

Analysts Offer Insights on Healthcare Companies: TG Therapeutics (NASDAQ: TGTX), Syndax Pharmaceuticals (NASDAQ: SNDX) and DaVita (NYSE: DVA)

Yigal Nochomovitz

Citi

€48.76

Buy

173.31%

Upside

Reiterated

08/05/26

Syndax Buy Rating Reaffirmed as Analyst Sees Transitory Demand Weakness, Strong Menin Positioning and Pipeline Catalysts Supporting Unchanged $57 Target

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

08/04/26

Phil Nadeau Reiterates Buy on Syndax, Citing Strong Revuforj Trajectory and Potential $2B Peak U.S. Sales

Corinne Johnson

Goldman Sachs

€29.08

Buy

63.03%

Upside

Reiterated

07/14/26

Syndax: Strengthening Pipeline and R&D Outlook Support Buy Rating and Unchanged $34 Price Target

Bradley Canino

Guggenheim

€26.52

Buy

48.64%

Upside

Reiterated

07/14/26

Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (NASDAQ: SNDX) and Rhythm Pharmaceuticals (NASDAQ: RYTM)

Faisal Khurshid

Jefferies

€34.22→€31.65

Buy

77.41%

Upside

Reiterated

05/01/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Centene (NYSE: CNC) and Syndax Pharmaceuticals (NASDAQ: SNDX)

Salim Syed

Mizuho Securities

€38.49→€36.78

Buy

106.18%

Upside

Reiterated

03/30/26

Mizuho Securities Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX)

Justin Zelin

BTIG

€47.9

Buy

168.51%

Upside

Reiterated

01/02/26

Syndax Pharmaceuticals (SNDX) Gets a Buy from BTIG

Mayank Mamtani

B. Riley Securities

€28.23

Buy

58.23%

Upside

Reiterated

10/03/25

Syndax Pharmaceuticals (SNDX) Gets a Buy from B. Riley Securities

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Dai

UBS

€31.65→€28.23

Buy

58.23%

Upside

Assigned

08/21/26

Syndax price target lowered to $33 from $37 at UBSSyndax price target lowered to $33 from $37 at UBS

Stephen Willey

Stifel Nicolaus

€34.22

Buy

91.79%

Upside

Reiterated

08/14/26

Analysts' Top Healthcare Picks: Ascendis Pharma (ASND), Quantum-Si (QSI)

Anupam Rama

J.P. Morgan

€37.64→€34.22

Buy

91.79%

Upside

Reiterated

08/11/26

Syndax price target lowered to $40 from $44 at JPMorganSyndax price target lowered to $40 from $44 at JPMorgan

Etzer Darout

Barclays

€31.65

Buy

77.41%

Upside

Reiterated

08/05/26

Analysts' Top Healthcare Picks: Syndax Pharmaceuticals (SNDX), Align Tech (ALGN)

Andres Y. Maldonado

H.C. Wainwright

€34.22→€32.51

Buy

82.20%

Upside

Reiterated

08/05/26

Syndax price target lowered to $38 from $40 at H.C. WainwrightSyndax price target lowered to $38 from $40 at H.C. Wainwright

Jason Zemansky

Bank of America Securities

€22.24

Buy

24.67%

Upside

Reiterated

08/05/26

Analysts Offer Insights on Healthcare Companies: TG Therapeutics (NASDAQ: TGTX), Syndax Pharmaceuticals (NASDAQ: SNDX) and DaVita (NYSE: DVA)

Yigal Nochomovitz

Citi

€48.76

Buy

173.31%

Upside

Reiterated

08/05/26

Syndax Buy Rating Reaffirmed as Analyst Sees Transitory Demand Weakness, Strong Menin Positioning and Pipeline Catalysts Supporting Unchanged $57 Target

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

08/04/26

Phil Nadeau Reiterates Buy on Syndax, Citing Strong Revuforj Trajectory and Potential $2B Peak U.S. Sales

Corinne Johnson

Goldman Sachs

€29.08

Buy

63.03%

Upside

Reiterated

07/14/26

Syndax: Strengthening Pipeline and R&D Outlook Support Buy Rating and Unchanged $34 Price Target

Bradley Canino

Guggenheim

€26.52

Buy

48.64%

Upside

Reiterated

07/14/26

Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (NASDAQ: SNDX) and Rhythm Pharmaceuticals (NASDAQ: RYTM)

Faisal Khurshid

Jefferies

€34.22→€31.65

Buy

77.41%

Upside

Reiterated

05/01/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Centene (NYSE: CNC) and Syndax Pharmaceuticals (NASDAQ: SNDX)

Salim Syed

Mizuho Securities

€38.49→€36.78

Buy

106.18%

Upside

Reiterated

03/30/26

Mizuho Securities Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX)

Justin Zelin

BTIG

€47.9

Buy

168.51%

Upside

Reiterated

01/02/26

Syndax Pharmaceuticals (SNDX) Gets a Buy from BTIG

Mayank Mamtani

B. Riley Securities

€28.23

Buy

58.23%

Upside

Reiterated

10/03/25

Syndax Pharmaceuticals (SNDX) Gets a Buy from B. Riley Securities

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Syndax Pharmaceuticals

3 Months

Phil NadeauTD Cowen

Success Rate

10/19 ratings generated profit

Average Return

+10.65%

Copying Phil Nadeau's trades and holding each position for 3 Months would result in 52.63% of your transactions generating a profit, with an average return of +10.65% per trade.

1 Year

Phil NadeauTD Cowen

Success Rate

11/19 ratings generated profit

Average Return

+18.72%

Copying Phil Nadeau's trades and holding each position for 1 Year would result in 57.89% of your transactions generating a profit, with an average return of +18.72% per trade.

2 Years

Jason ZemanskyBank of America Securities

Success Rate

14/25 ratings generated profit

Average Return

+17.08%

Copying Jason Zemansky's trades and holding each position for 2 Years would result in 56.00% of your transactions generating a profit, with an average return of +17.08% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1T3 Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1T3 has received 25 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 1T3 average Analyst price target in the past 3 months is 31.94.

Each month's total comprises the sum of three months' worth of ratings.

1T3 Financial Forecast

1T3 Earnings Forecast

Next quarter’s earnings estimate for 1T3 is -€0.41 with a range of -€0.49 to -€0.27. The previous quarter’s EPS was -€0.47. 1T3 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1T3 has Performed in-line its overall industry.

1T3 Sales Forecast

Next quarter’s sales forecast for 1T3 is €70.82M with a range of €67.46M to €73.56M. The previous quarter’s sales results were €62.26M. 1T3 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1T3 has Performed in-line its overall industry.

1T3 Stock Forecast FAQ

What is DE:1T3’s average 12-month price target, according to analysts?

Based on analyst ratings, Syndax Pharmaceuticals Inc’s 12-month average price target is 31.94.

What is DE:1T3’s upside potential, based on the analysts’ average price target?

Syndax Pharmaceuticals Inc has 79.01% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Syndax Pharmaceuticals Inc a Buy, Sell or Hold?

Syndax Pharmaceuticals Inc has a consensus rating of Strong Buy, which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.

What is Syndax Pharmaceuticals Inc’s share price target?

The average share price target for Syndax Pharmaceuticals Inc is 31.94. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €48.76 ,and the lowest forecast is €22.24. The average share price target represents 79.01% Increase from the current price of €17.84.

What do analysts say about Syndax Pharmaceuticals Inc?

Syndax Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of Syndax Pharmaceuticals Inc?

To buy shares of DE:1T3, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Syndax Pharmaceuticals (1T3) Stock Forecast & Price Target

1T3 Analyst Ratings

1T3 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Syndax Pharmaceuticals

1T3 Analyst Recommendation Trends

1T3 Financial Forecast

1T3 Earnings Forecast

1T3 Sales Forecast

1T3 Stock Forecast FAQ

Detailed List of Analyst Forecasts